



BIBCOL

Bharat Immunologicals & Biologicals Corporation Limited

CIN – L24232UP1989GOI010542 (A Govt. of India Undertaking)

Regd. Office: Vill. Chola, Bulandshahr(UP)-Pin 203203

Phone 9458096110, Tele Fax -05732 238757

Email – sklalacs@yahoo.co.in Website- www.bibcol.com

No.BIB/CS/SE/UAFR-Q3/2022-23

Date 10.02.2023

To
The Bombay Stock Exchange
Listing Department
Phiroze Jeejeebhoy Towers,
25, Dalal Street,
Mumbai – 400 001.

Sub: Submission of Unaudited Quarterly Financial Results for the quarter and nine months ended December 2022 along with Limited Review Report


Sir/Madam,

In compliance of SEBI LODR with Stock Exchange, please find enclosed the Unaudited Quarterly Financial Results for the quarter and nine months ended December 2022 along with Limited Review Report, approved by the Board of the Company in its Meeting held on 09.02.2023.

It is requested to kindly take the above on record please.

Regards,




(Sandip Kumar Lal)
Company Secretary



RESHMA & COMPANY

CHARTERED ACCOUNTANTS

Ref. No.

Date 31.01.2023

LIMITED REVIEW REPORT

TO THE MEMBERS OF BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LIMITED,

We have reviewed the accompanying statements of unaudited financial statement of **BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LIMITED**, for the period of 01st October, 2022 to 31st December, 2022. This statement is the responsibility of the company's Management and has been approved by the station in charge. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the standard on review engagement (SRE) 2410- 'Review of interim financial information performed by the independent auditor of the entity' The standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial result prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Reshma and Company
Chartered Accountants
FRN No.007593C


CA. Deepak Mitta
Partner
M. No. 074979
Place: Ghaziabad
Date: 31.01.2023
UDIN: 23074979BGYDJV7446



H.O: Krishna Niwas, Raje Babu Road, Behind TVS Show Room, Bulandsaher. Ph: 9810371373.
B.O: 1104, Nirmal Tower, 26 Barakhambha Road, Connaught Place, New Delhi - 110001, Ph: 011-43596490
B.O: C-51, RDC, Raj Nagar, Ghaziabad - 201001, Ph. - 0120-6540993, 0120-4110788, Cell: 9811546688
reshmaandco@gmail.com; reshmamittal@reshmaandcompany.com; www.reshmaandcompany.com

Part I
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31-12-2022
Selected Information for the Period Ended 31-12-2022

(INR in Lakh)						
S. No	Particulars	3 Months Ended on 31-12-2022	Preceding 3 Months Ended on 30-09-2022	Corresponding 3 Months Ended in the previous year 31-12-2021	Nine Months Ended on 31-12-2022	Previous Year Ended as on 31-03-2022
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	INCOME					
	a) Income from Operations	-	2,647.96	1,743.05	3,695.88	7,838.80
	b) Other Income	10.24	31.95	12.38	56.55	110.23
	Total Revenue (1)	10.24	2,679.91	1,755.43	3,752.43	7,949.03
2	EXPENDITURE					
	a) Cost of Material Consumed	651.08	10.61	1,944.58	-	-
	b) Purchase of Stock in Trade	-	-	-	3,303.32	5,918.51
	c) Change in Inventory of Finished Goods, Work in Progress and Stock in Trade	-783.48	2,427.29	-1,049.60	-188.92	44.46
	d) Employees Benefits	409.99	394.98	319.06	1,200.30	1,384.91
	e) Finance Cost	166.83	174.22	153.85	499.09	559.17
	f) Depreciations and Amortization Expense	3.65	3.65	4.07	10.96	21.27
	g) Other Expense	195.07	65.08	427.45	586.88	989.46
	Total Expense (2)	643.15	3,075.83	1,799.41	5,411.64	8,917.77
3	Profit/ (Loss) before exceptional items (1-2)	-632.91	-395.92	-43.98	-1,659.20	-968.74
4	Tax Expense					
	a) Current Tax	-	-	-	-	-
	b) Deferred Tax	-164.56	-87.60	-11.04	-382.87	-93.38
5	Profit/ (Loss) from continuing Operations (3-4)	-468.35	-308.31	-32.94	-1,276.33	-875.36
6	Other Comprehensive Income/(Loss) (Net of Taxes)	-	-	-	-	-
7	Total Comprehensive Income/ (Loss) for the period (5+6)	-468.35	-308.31	-32.94	-1,276.33	-875.36
8	Paid Up Equity Share Capital (Face Value of INR 10/- each)	4,318.00	4,318.00	4,318.00	4,318.00	4,318.00
9	Earning Per Share (of INR 10/- each) not annualized					
	a) Basic	-1.08	-0.71	-0.08	-1.80	-2.03
	b) Diluted	-1.08	-0.71	-0.08	-1.80	-2.03

Note:- Refer our Note Separately



S. K.

Part II
Selected Information for the Period Ended 31-12-2022

S. No	Particulars	3 Months Ended on 31-12-2022	Preceding 3 Months Ended on 30-09-2022	Corresponding 3 Months Ended in the previous year 31-12-2021	Nine Months Ended on 31-12-2022	Previous Year Ended as on 31-03-2022
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
A1	PARTICULARS OF SHAREHOLDING					
	Public shareholding					
	- Number of Shares	17,594,000.00	17,594,000.00	17,594,000.00	17,594,000.00	17,594,000.00
	- Percentage of shareholding	40.75	40.75	40.75	40.75	40.75
A2	Promoters and Promoters Group shareholding					
	a) Pledged/ Encumbered					
	- Number of Shares	-	-	-	-	-
	- Percentage of shareholding (as a% of the total shareholding of promoter and promoter group)	-	-	-	-	-
	- Percentage of shareholding (as a% of the total share capital of the company)	-	-	-	-	-
	b) Non - encumbered					
	- Number of Shares	25,586,000.00	25,586,000.00	25,586,000.00	25,586,000.00	25,586,000.00
	- Percentage of shareholding (as a% of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00
	- Percentage of shareholding (as a% of the total share capital of the company)	59.25	59.25	59.25	59.25	59.25
B	Particulars	3 Months Ended on 31-12-2022				
	INVESTOR COMPLAINTS					
	Pending at the beginning of the quarter	0				
	Received during the quarter	0				
	Disposed of during the quarter	0				
	Remaining unresolved at the end of the quarter	0				

Segment Reporting for the Period Ended 31-12-2022

(INR in Lakhs)

S. No	Particulars	3 Months Ended on 31-12-2022	Preceding 3 Months Ended on 30-09-2022	Corresponding 3 Months Ended in the previous year 31-12-2021	Nine Months Ended on 31-12-2022	Previous Year Ended as on 31-03-2022
1	SEGMENT REVENUE					
	Oral Polio Vaccine	-	2,647.96	1,742.95	3,695.86	7,835.26
	Zinc Dispersible Tablets	-	-	-	-	-
	BIB Sweet Tablets	-	-	-	-	0.02
	BIBSANIT	-	-	0.10	0.04	3.52
	Less: Inter segment revenue	-	-	-	-	-
	Net Sales/ Income from operations	-	2,647.96	1,743.05	3,695.90	7,838.80
2	SEGMENT RESULTS (Profit Before Tax)					
	Oral Polio Vaccine	-632.91	-308.31	-43.93	-1,659.20	-875.16
	Zinc Dispersible Tablets	-	-	-0.04	-	-
	BIB Sweet Tablets	-	-	-	-	-
	BIBSANIT	-	-	-0.01	-	-
	Less: Unallocable expenditure net off Unallocable Income	-	-	-	-	-0.20
	Total Profit before Tax	-632.91	-308.31	-43.98	-1,659.20	-875.36
3	CAPITAL EMPLOYED (Segment Assets less Liabilities)					
	Oral Polio Vaccine	19,144.51	19,144.51	19,140.69	19,144.51	19,144.51
	Zinc Dispersible Tablets	-226.10	-226.10	-226.05	-226.10	-226.10
	BIB Sweet Tablets	-	-	-	-	-
	BIBSANIT	-	-	-	-	-
	Others*	1,109.86	1,109.86	-861.18	1,109.86	1,109.86
	Total Capital employed	20,028.27	20,028.27	12,728.94	20,028.27	20,028.27

Note : * Represents OCV, DMK, Up-gradation of OPV & BOPV Projects

S. S. S.

Notes to the Results

1. The above Un-Audited results for the Quarter ended 31st December, 2022 have been review by the Audit Committee and were taken on record by the Board of Directors in their meeting held on 9th February 2022.
2. Valuation of Closing Stock has been done on the basis of Net realizable value.
3. In quarters, depreciation has been charged on the basis of Companies Act 2013.
4. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rule 2015 (Ind AS), prescribed under Section 133 of the Companies Act, 2013, and other recognized accounting practices and policies to the extent applicable.
5. The format for unaudited quarterly results as prescribed in SEBI's Circular dated November 30, 2015 has been modified to comply with requirements of SEBI's Circular dated July 5, 2016. Ind AS and Schedule III (Division II) to the Companies Act, 2013 applicable to companies that are required to comply with Ind AS.
6. The statement does include Ind AS compliant results for the preceding quarter and previous year ended 31st December, 2022.
7. Segment information as per Ind AS 108 has been given above as Segment Reporting. The Company is currently engaged in production of Oral Polio Vaccine, Zinc Dispersible Tablets and Sweetener.
8. The Ind As complaint corresponding figures in the previous year have been subjected to review / audited. However, the company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs.
9. The reconciliation of net profit or loss reported in accordance with Indian GAAP to total comprehensive income in accordance with Ind AS as given below: For Table. kindly refer Corporate Announcements on www.bscindia.com.
10. Previous year/quarter figures have been regrouped/re-arranged wherever necessary, to make it comparable.

Date:- 09.02.2023

Set


(Chaitanya Murti)
Managing Director